Impact of TRIM5α and TRIM22 Genes Expression on the Clinical Course of Coronavirus Disease 2019.

Coronavirus disease 2019 Tripartite motif-containing 22 Tripartite motif-containing 5α cycle threshold value mild infection severe infection

Journal

Archives of medical research
ISSN: 1873-5487
Titre abrégé: Arch Med Res
Pays: United States
ID NLM: 9312706

Informations de publication

Date de publication:
02 2023
Historique:
received: 22 09 2022
revised: 30 11 2022
accepted: 23 12 2022
pubmed: 10 1 2023
medline: 8 3 2023
entrez: 9 1 2023
Statut: ppublish

Résumé

The innate immune response in humans involves a wide variety of factors, including the tripartite motif-containing 5α (TRIM5α) and 22 (TRIM22) as a cluster of genes on chromosome 11 that have exhibited antiviral activity in several viral infections. We analyzed the correlation of the expression of TRIM5α and TRIM22 with the severity of Coronavirus Disease 2019 (COVID-19) in blood samples of 330 patients, divided into two groups of severe and mild disease, versus the healthy individuals who never had contact with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The transcription level of TRIM5α and TRIM22 was determined by quantitative real-time polymerase chain reaction (qPCR). The laboratory values were collected from the patients' records. The expression of both genes was significantly lower in the severe group containing the hospitalized patients than in both the mild group and the control group. However, in the mild group, TRIM22 expression was significantly higher (p <0.0001) than in the control group while TRIM5α expression was not significantly different between these two groups. We found a relationship between the cycle threshold (Ct) value of patients and the expression of the aforementioned genes. The results of our study indicated that lower Ct values or higher RNA viral load might be associated with the downregulation of TRIM5α and TRIM22 and the severity of COVID-19. Additional studies are needed to confirm the results of this study.

Identifiants

pubmed: 36621405
pii: S0188-4409(22)00187-4
doi: 10.1016/j.arcmed.2022.12.010
pmc: PMC9794484
pii:
doi:

Substances chimiques

Repressor Proteins 0
Tripartite Motif Proteins 0
TRIM22 protein, human 0
Minor Histocompatibility Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-112

Informations de copyright

Copyright © 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest The authors declare that there are no conflicts of interest.

Références

Front Microbiol. 2012 Mar 15;3:97
pubmed: 22435067
J Med Virol. 2022 Jul;94(7):2977-2985
pubmed: 35257387
Hum Genomics. 2022 Aug 26;16(1):33
pubmed: 36028902
Nat Methods. 2019 Apr;16(4):327-332
pubmed: 30886410
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
J Gen Virol. 2009 Mar;90(Pt 3):536-545
pubmed: 19218198
Eur J Hum Genet. 2021 Jun;29(6):1019-1026
pubmed: 33649539
J Proteome Res. 2021 May 7;20(5):2224-2239
pubmed: 33666082
Front Cell Infect Microbiol. 2021 Sep 21;11:689707
pubmed: 34621686
Hepatology. 2009 Aug;50(2):424-33
pubmed: 19585648
Virus Res. 2015 Nov 2;209:11-22
pubmed: 25678267
Gene. 2018 Nov 15;676:95-100
pubmed: 30017737
Nat Immunol. 2004 Nov;5(11):1109-15
pubmed: 15496950
Viruses. 2022 Feb 08;14(2):
pubmed: 35215944
Vaccines (Basel). 2017 Aug 22;5(3):
pubmed: 28829373
Nature. 2011 Apr 28;472(7344):481-5
pubmed: 21478870
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
mSphere. 2018 Apr 4;3(2):
pubmed: 29624498
Cells. 2021 Jul 23;10(8):
pubmed: 34440633
Emerg Infect Dis. 2015 Nov;21(11):2029-35
pubmed: 26488195
Proc Natl Acad Sci U S A. 2006 May 9;103(19):7454-9
pubmed: 16648259
Bratisl Lek Listy. 2020;121(10):733-741
pubmed: 32955906
Plant Mol Biol. 2012 Jan 31;:
pubmed: 22290409
Nat Microbiol. 2019 Dec;4(12):2044-2051
pubmed: 31636416
Adv Exp Med Biol. 2012;770:27-37
pubmed: 23630998
J Virol. 2015 Oct 14;90(1):308-16
pubmed: 26468522
Am J Trop Med Hyg. 2020 Nov;103(5):2019-2021
pubmed: 32996443
Virol J. 2021 Nov 14;18(1):221
pubmed: 34775984
Viruses. 2021 Mar 10;13(3):
pubmed: 33801908
Front Genet. 2021 Mar 16;12:599261
pubmed: 33796130
Elife. 2020 Sep 15;9:
pubmed: 32930662
PLoS Pathog. 2007 Dec;3(12):e197
pubmed: 18159944
Diagnostics (Basel). 2021 Jun 15;11(6):
pubmed: 34203738
Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205
pubmed: 32603425
Cell Mol Immunol. 2017 Sep;14(9):794-796
pubmed: 28782753
Mol Biol Int. 2012;2012:153415
pubmed: 22649727
Future Microbiol. 2010 Jan;5(1):23-41
pubmed: 20020828
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
J Virol. 2013 Apr;87(8):4523-33
pubmed: 23408607
J Virol. 2012 Feb;86(3):1717-27
pubmed: 22114335
Annu Rev Virol. 2018 Sep 29;5(1):385-405
pubmed: 29949725

Auteurs

Rezvan Tavakoli (R)

Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran.

Pooneh Rahimi (P)

Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran; Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.

Mojtaba Hamidi-Fard (M)

Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran; Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.

Sana Eybpoosh (S)

Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.

Delaram Doroud (D)

Quality Control Department, Production and Research Complex, Pasteur institute of Iran, Tehran, Iran.

Seyed Amir Sadeghi (SA)

Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran.

Mohammadali Zaheri Birgani (M)

Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran.

Mohammadreza Aghasadeghi (M)

Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran; Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.

Abolfazl Fateh (A)

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran. Electronic address: afateh2@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH